Sean Stanton has dedicated the last 30 years of his career to creating successful, high-performing research sites.
To date, Sean has led the start-up of 27 clinical trial sites, six inpatient hospitals, and 19 outpatient clinics. More than 5,000 clinical trials have been conducted at these sites, leading to more than 50 drug approvals. Prozac was the first approved drug Sean worked on, followed by many other well-known drugs used in a variety of therapeutic areas (e.g., General Medicine, Vaccine, Women’s Health, Diabetes; Pain; Mental Health; Heart Disease; Oncology; Neurodegenerative Diseases; Sleep Disorders; etc.). In these trials Sean directed recruitment for the screening of 2,000 to 6,000 patients annually. A pioneer in patient recruitment, Sean was the first to pre-screen for screens and was on the forefront of direct-to consumer advertising, circa 1997.
Sean brings innovative thinking to clinical research in all aspects of site practices, from purchasing and resourcing, to the use of benchmarking and metrics in business planning to guide strategic clinical trial practice growth. Sean is frequently sought as an industry expert to speak on topics including building successful clinical research sites; patient recruiting, particularly difficult to recruit populations and decreasing screen fail rates; protocol design; site selection; patient reported outcomes and other areas. He has advised hospitals and institutions on research site growth strategy and mergers and acquisitions at the site level.
Sean is the co-founder of the K2 Medical Research, highly successful clinical research site dedicated to beating Alzheimer’s Disease. Prior to this is was the co-Founder of the largest single site on the planet called Compass Research, which was acquired and successfully integrated in Bioclinica Research Network and now part of Thermo-Fisher’s Healthcare System. Sean is now leading a team of dedicated researchers in a new endeavor consulting for the top pharmaceutical and biotech companies around the world, offering his knowledge and expertise of connecting problems to solutions through K2 Medical Research.
Sean is a founding member of DAVOS Alzheimer’s Collaborative (DAC), Strategic Advisor to The Global Alzheimer’s Platform, Strategic Growth and Business Strategy to C2N Diagnostics (First Blood test for Alzheimer’s). Board member for the Alzheimer’s Disease and Resource Center (ADCR). Board of Trustees member at Wester University Health Sciences. Board Member to Orlando Chapter of Young Presidents Organization (YPO).
Early in his career Sean held numerous pre-clinical and clinical research positions in neuroscience. He began his career as a clinical research coordinator at the University of Cincinnati Medical Center, Department of Psychiatry. Sean has a bachelor’s degree in Biology from the University of Cincinnati.
